Association of p27(Kip1) levels with recurrence and survival in patients with stage C prostate carcinoma

Journal of the National Cancer Institute

Volumn 90, Issue 12, 1998, Pages 916-920

  Cote, Richard J ^a,b   Shi, Yan ^a   Groshen, Susan ^b   Feng, An Chen ^b   Cordon Cardo, Carlos ^c   Skinner, Donald ^b   Lieskovosky, Gary ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN P27; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DIAGNOSTIC AGENT; ENZYME INHIBITOR; MICROTUBULE ASSOCIATED PROTEIN; MONOCLONAL ANTIBODY; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL NUCLEUS; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CARCINOMA; PROSTATECTOMY; DISEASE COURSE; DRUG ANTAGONISM; FOLLOW UP; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PROSTATE TUMOR; SURVIVAL;

AGED; ANTIBODIES, MONOCLONAL; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; DISEASE PROGRESSION; ENZYME INHIBITORS; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 0032540544     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.12.916     Document Type: Article

References (31)

1. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990;143: 747-52.
2. Steeg PS, Abrams JS. Cancer prognostics: past, present and p27. Nat Med 1997;3:152-4.
3. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994;78:59-66.
4. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3:231-4.
5. kip1 and cyclin E, alone or in a combination, correlate with survival in young breast cancer patients. Nat Med 1997;3:222-5.
6. Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997;3:227-30.
7. American Joint Committee on Cancer. Genitourinary cancers. In: Manual for staging of cancer. 4th ed. Philadelphia: Lippincott, 1992:183.
8. Gleason DF. Histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M, editor. Urologic pathology. The prostate. Philadelphia: Lea & Febiger, 1977: 171-98.
9. Gibbons RP, Cole BS, Richardson RG, Correa RJ Jr, Brannen GE, Mason JT, et al. Adjuvant radiotherapy following radical prostatectomy: results and complications. J Urol 1986;135:65-8.
10. Shi SR, Cote RJ, Taylor CR. Antigen retrieval immunohistochemistry: past, present, and future. J Histochem Cytochem 1997;45:327-43.
11. 0 state) in fibroblasts. J Biol Chem 1996;271:18337-41.
12. Mantel N. Chi square tests with one degree of freedom: extensions of the Mantel-Haenszel procedure. J Am Stat Assoc 1963;58:690-700.
13. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
14. Miller RG Jr. Survival analysis. New York: John Wiley & Sons, 1981;51,114-8.
15. Breslow N. Comparison of survival curves. In: Buyse ME, Staquet MJ, Sylvester RJ, editors. Cancer clinical trials: methods and practices. Oxford: Oxford University Press, 1988: 398-403.
16. Pike MC. Contribution to the discussion of the paper by R. Peto and J. Peto, "Asymptotically efficient rank invariant procedures." J Roy Stat Soc Series A 1972;135:201-3.
17. Berry G, Kitchin RM, Mock PA. A comparison of two simple hazard ratio estimators based on the logrank test. Stat Med 1991;10:749-55.
18. Lawless JF. Statistical models and methods for lifetime data. New York: John Wiley & Sons, 1982:345-54.
19. Johansson JE, Adami HO, Andersson SO, Bergstrom R, Holmberg L, Krusemo UB. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 1992;267: 2191-6.
20. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331:1259-64.
21. Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 1995;147: 545-60.
22. Salem CE, Tomasic NA, Elmajian DA, Esrig D, Nichols PW, Taylor CR, et al. p53 protein and gene alterations in pathological stage C prostate carcinoma. J Urol 1997;158:510-4.
23. Aprikian AG, Sarkis AS, Fair WR, Zhang ZF, Fuks Z, Cordon-Cardo C. Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J Urol 1994;151:1276-80.
24. Grignon DJ, Caplan R, Sarkar FH, Lawton CA, Hammond EH, Pilepich MV, et al. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst 1997;89:158-65.
25. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 1996;85:721-32.
26. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, et al. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996;85:707-20.
27. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 1996;85:733-44.
28. Ponce-Castaneda MV, Lee MH, Latres E, Polyak K, Lacombe L, Montgomery K, et al. p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res 1995;55: 1211-4.
29. Kip1 in primary breast carcinomas. Hum Genet 1996;97:91-4.
30. kip1 expression in benign postatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst 1998. In press.
31. Kip1 on resistance of tumor cells to anticancer agents. Nat Med 1996;2:1204-10.